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Reactive Oxygen Species, Vascular Noxs, and Hypertension:
Focus on Translational and Clinical Research
Augusto C. Montezano and Rhian M. Touyz
Abstract
Significance: Reactive oxygen species (ROS) are signaling molecules that are important in physiological pro-
cesses, including host defense, aging, and cellular homeostasis. Increased ROS bioavailability and altered redox
signaling (oxidative stress) have been implicated in the onset and/or progression of chronic diseases, including
hypertension. Recent Advances: Although oxidative stress may not be the only cause of hypertension, it am-
plifies blood pressure elevation in the presence of other pro-hypertensive factors, such as salt loading, activation
of the renin-angiotensin-aldosterone system, and sympathetic hyperactivity, at least in experimental models. A
major source for ROS in the cardiovascular-renal system is a family of nicotinamide adenine dinucleotide
phosphate oxidases (Noxs), including the prototypic Nox2-based Nox, and Nox family members: Nox1, Nox4,
and Nox5. Critical Issues: Although extensive experimental data support a role for increased ROS levels and
altered redox signaling in the pathogenesis of hypertension, the role in clinical hypertension is unclear, as a
direct causative role of ROS in blood pressure elevation has yet to be demonstrated in humans. Nevertheless,
what is becoming increasingly evident is that abnormal ROS regulation and aberrant signaling through redox-
sensitive pathways are important in the pathophysiological processes which is associated with vascular injury
and target-organ damage in hypertension. Future Directions: There is a paucity of clinical information related to
the mechanisms of oxidative stress and blood pressure elevation, and a few assays accurately measure ROS
directly in patients. Such further ROS research is needed in humans and in the development of adequately
validated analytical methods to accurately assess oxidative stress in the clinic. Antioxid. Redox Signal. 20, 164–182.
Introduction
Hypertension is a multifactorial, complex disorder, in-volving many organ systems (41, 215). Factors that are
important in the development of hypertension include acti-
vation of the sympathetic nervous system, up-regulation of
the renin-angiotensin-aldosterone system, altered G protein-
coupled receptor signaling, and inflammation (81, 214). Re-
cent studies also implicate a role of the immune system in
hypertension (82, 175). Common to these processes is oxida-
tive stress (excess levels of oxidants over antioxidants), due,
mainly, to increased production of reactive oxygen species
(ROS), decreased nitric oxide (NO) levels, and reduced anti-
oxidant capacity in the cardiovascular, renal, and central
nervous systems (Fig. 1) (208, 220).
ROS, including superoxide (O2
 - ) and hydrogen peroxide
(H2O2), were originally considered harmful metabolic by-
products of mitochondrial energetics and cell metabolism.
However, ROS are now recognized to have important phys-
iological functions through theirmodulation of the redox state
of signaling molecules (52). ROS influence many signaling
pathways, including mitogen-activated protein kinases
(MAPK), tyrosine kinases, Rho kinase, transcription factors
(NFjB, AP-1, and HIF-1), and protein tyrosine phosphatases
that impact cardiovascular, renal, and neural cell function
(26, 134, 158, 161, 189). ROS increase intracellular free Ca2 +
concentration ([Ca2 + ]i) through ion channel activation andup-
regulate protooncogene and proinflammatory gene expres-
sion and activity (40, 199). Uncontrolled generation of ROS
promotes oxidative stress amd consequent damage to DNA,
proteins, and lipids, leading to cell injury and cytotoxicity (96,
115, 118). Physiologically, ROS regulate cellular processes
such as differentiation, proliferation, apoptosis, cell cycle,
migration, secretion, cytoskeletal organization, activation of
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transcription factors, and gene expression (71, 98, 212). In the
vascular system, ROS play a physiological role in controlling
endothelial function and vascular tone and a pathophysio-
logical role in processes underlying endothelial dysfunction,
hyperreactivity, inflammation, and vascular remodeling
in cardiovascular diseases, including hypertension (4, 19, 200,
218).
ROS are usually produced from cellular respiration and
metabolic processes as byproducts via activation of enzymes
such as xanthine oxidoreductase, uncoupled NO synthase
(NOS), and mitochondrial respiratory enzymes (2, 65, 150,
186) (Fig. 2). In addition, ROS are produced by nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases (Nox).
Noxs, of which there are seven isoforms, and that function
primarily as ROS-generating enzymes, are an important
source of O2
 - and H2O2 in the cardiovascular system (209).
When dysregulated Noxs play a role in increased ROS pro-
duction, it leads to endothelial dysfunction and vascular re-
modeling in hypertension.
The relationship between ROS and blood pressure was first
suggested in the 1960s (170), but it was in the early 2000s that
this associationwas explored in detail when it was shown that
angiotensin II (Ang II)-induced hypertension in rats increases
vascular ROS production via non-phagocytic NADPH oxi-
dase activation (162). Most experimental models of hyper-
tension exhibit some degree of oxidative stress (48, 67, 93, 95,
236). Moreover, mice with reduced antioxidant enzyme sys-
tems and those deficient in NADPH oxidase have higher
blood pressures than those with intact systems. Based on ex-
tensive experimental data, it has been suggested that oxida-
tive stress is causally associated with hypertension, at least in
animal models.
In clinical medicine, the direct relationship between ROS
and hypertension is not convincing, and there is still no
definitive proof that oxidative stress is a direct cause of
hypertension in humans. In fact, despite extensive data in
the literature implicating a role for ROS and oxidative stress
in many chronic diseases, such as cardiovascular disease,
diabetes, cancer, and kidney disease, there are very few
clinical conditions that are directly due to altered ROS levels.
These include vitiligo, neurodegenerative diseases, and
progeria (67, 99, 117, 145, 172, 216). With regard to clinical
hypertension, most studies examining ROS are based on
associations between plasma or urine markers of oxidative
stress and blood pressure. Biomarkers of cell damage due
to systemic oxidative stress, such as plasma thiobarbituric
FIG. 1. Systemic oxidative stress in humans: implications in hypertension. Pathophysiological levels of reactive oxygen
species (ROS) will lead to a series of deleterious effects in the human body. In the brain, ROS increase the production and
release of vasoactive neurotransmitters, which, in turn, will increase or decrease vascular resistance, an effect that influences
blood pressure. In the kidney, ROS increases the production and the release of many vasoactive agents, including angiotensin
II (Ang II) and aldosterone, which, in turn, influence cardiac, vascular, and renal function through redox-sensitive processes.
ROS influence processes that are involved in vascular remodeling, endothelial dysfunction, fibrosis, and inflammation, which
are characteristic features in hypertension. Moreover, in the heart, ROS have been linked to increased contractility, fibrosis
and cardiac remodeling; reflecting in an increase in cardiac output and blood pressure. All of these ROS-related effects impact
the development of hypertension and its target organ damage, predisposing to stroke, heart failure, and chronic kidney
disease (CKD).
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acid-reactive substances (TBARS) and 8-epi-isoprostanes, are
elevated in patients with hypertension (45, 116). Antioxidant
capacity and levels of antioxidant vitamins and enzymes
have been shown to be reduced in patients with hyperten-
sion (66, 107). Such studies between hypertension and oxi-
dative stress are purely correlative and are far from proving
cause.
Hence, despite the notion that oxidative stress underlies
hypertension, there is still little solid evidence for this at the
clinical level. Possible reasons relate to a paucity of informa-
tion on molecular mechanisms of ROS biology in human tis-
sue, lack of adequate methods to evaluate ROS in the clinical
setting, and inappropriately designed clinical trials to evalu-
ate the effects of antioxidant therapy on hypertension. It is
also possible that, although oxidative stress may be important
in pathophysiological mechanisms that are associated with
cardiac, vascular, renal, and neural dysfunction and re-
modeling, which could influence blood pressure (Fig. 1), it
may not be an important primary causative factor in the
pathogenesis of hypertension in humans.. These themes will
be developed and discussed in the present review. While it is
appreciated that ROS have an impact on many systems that
influence blood pressure regulation and development of hy-
pertension, here, we will focus on the role of vascular ROS in
hypertension, highlighting translational research and clinical
studies.
Production of ROS in the Vascular System:
Spotlight on Noxs
Noxs are transmembrane-associated proteins that transfer
electrons across membranes, such that the final electron ac-
ceptor is O2 andO2
 - is generated (113). ThemammalianNox
family comprises seven isoforms: Nox1, Nox2, Nox3, Nox4,
Nox5, Duox1, and Duox2 (16, 113, 182). Nox1, 2, 4, and 5 are
expressed in multiple tissues; whereas Nox3 and the Duoxs
are more tissue specific, with Nox3 expressed in the inner ear
and Duox1/2 in the thyroid gland. All Noxs are transmem-
brane proteins that have a core catalytic subunit (Nox) and a
number of regulatory subunits (Fig. 3).
The prototypical Nox is Nox2 (phagocytic NADPH oxi-
dase) and comprises five subunits: p47phox, p67phox,
p40phox, which are cytosolic regulatory proteins, p22phox, a
membrane regulatory protein, and gp91phox, which is the
catalytic subunit (12). Nox2 is activated when the regulatory
subunit p47phox is phosphorylated, complexes with p67phox
and p40phox, and translocates to the cell membrane to in-
teract with p22phox and Nox2 to assemble the active oxidase,
which then transfers electrons from the substrate (NADPH) to
O2 forming O2
 - (119).
Nox1, Nox2, Nox4, and Nox5 have been identified in the
vascular system (24, 111). Hyperactivation of Noxs leads to
excessive ROS production that disrupts redox networks,
FIG. 2. Sources of ROS in cells. ROS production is regulated by many tightly controlled systems. ROS are produced either
as a byproduct of an enzyme or as the main product of nicotinamide adenine dinucleotide phosphate oxidase (Nox) activity.
Except for Nox, which has as its main function the formation of ROS, the other enzymes generate ROS as byproducts of
enzymatic activity. Uncoupled endothelial nitric oxide synthase (eNOS): In the absence of L-arginine or tetrahydrobiopterin,
the electrons in the enzyme reduce molecular oxygen to superoxide, instead of NO. Damaged or dysfunctional mitochondria
generate increased amounts of superoxide, creating a state of redox imbalance and consequent oxidative stress. Nox: The Nox
family comprises seven isoforms, where the generation of ROS is the main and only function. For these enzymes to be
biologically active, they require a number of subunits to assemble at the membrane in order to form ROS. Other enzymes that
generate ROS are xanthine oxidase, cyclooxygenase, lipoxygenase, glucose oxidase, and P450 mono-oxidases.
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which is usually regulated by thiol-dependent antioxidant
systems. This leads to oxidative stress, triggering molecular
processes, which, in the vasculature, contributes to vascular
injury and inflammation. The Noxs have been extensively
reviewed (7, 16, 53, 82, 113, 160), and only an overview of
recent developments is discussed here, focusing on the most
recently characterized isoform, Nox5.
Nox1
Nox1 is abundant in colon epithelium, but is also found in
endothelium, smooth muscle, fibroblasts, cardiomyocytes,
and microglia (151). It requires p22phox, p47phox (or its
homologue NoxO1 [Nox organizer 1]), and p67phox (or its
homologue NoxA1 [Nox activator 1]) for its activity. Nox1-
derived O2
 - is increased in a stimulus-dependent manner,
involving complex interactions between regulatory subunits
and the redox chaperone protein disulfide isomerase (54, 58).
In cultured endothelial and vascular smooth muscle cells
(VSMCs), Nox1 is up-regulated by mechanical factors (shear
stress), vasoactive agents (Ang II, aldosterone), and growth
factors (epidermal growth factor, platelet-derived growth
factor [PDGF]) (128, 159). Induction of Nox1 by Ang II may
involve mitochondria, possibly through a Ca2 + -dependent
mechanism (163). Nox1 is also activated by H2O2 in VSMCs.
Exogenous H2O2, which may enter cells via aquaporins, in-
creased Nox1-derived O2
 - generation, leading to hypertro-
phy, a process that is mediated via Ask1 (3).
Nox1 plays a role in VSMC migration, proliferation, and
extracellular matrix production, effects that are mediated by
cofilin (219). It has also been implicated in blood flow regu-
lation through a mechanism involving thrombospondin-1
(TSP1) and CD47 (46). Blockade of CD47 and Nox1 gene
silencing in vivo in rats improved TSP1-induced impairment
of tissue blood flow after ischemia reperfusion. These novel
data suggest a highly regulated process of ROS stimulation
and blood flow regulation promoted through direct TSP1/
CD47-mediated activation of Nox1 and define a regulatory
role for TSP1 via CD47, Nox1, and ROS in tissue injury and
reperfusion.
Nox1 expression/activity is increased in the vasculature in
models of cardiovascular disease, including hypertension,
atherosclerosis, diabetes, and hypercholesterolemia (50, 190).
Nox1-deficientmice have decreased expression of aortic AT1R
(130), which may contribute to blunted pressor actions of Ang
II infusion in these mice. Although there is extensive experi-
mental data suggesting a role for Nox1 in cardiovascular
disease, there is little information in humans, although ex-
pression of Nox1 and NoxA1 is increased in human athero-
sclerotic vessels (152).
Nox2
Nox2 is not only the catalytic subunit of the respiratory
burst Nox in phagocytes, but it is also expressed in vascular
cells (210), where it localizes in the cell membrane, as well as
FIG. 3. Nox activation in the cardiovascular system. Nox1, Nox2, Nox4, and Nox5 are members of the Nox family that are
expressed in the cardiovascular system. Nox2 is the classical Nox that is primarily characterized in leukocytes and related to
host defence responses. In order to be activated, cytosolic subunits (p47phox, p67phox, and Rac 1/2) should translocate from
the cytosol to the membrane and bind to the other two membrane-bound subunits, Nox2 and p22phox. ROS is generated
once the whole enzyme complex is formed. Nox1 activation is similar to Nox2, but it depends on the cytosolic subunits
NoxO1 (a homologue of p47phox) and NoxA1 (a homologue of p67phox) in order to be active. Nox4 only depends on
p22phox in order to be active, is constitutively activated, and ROS production is regulated by Poldip2. Nox5 does not depend
on any other subunits to be activated. It has four EF hands, which are binding sites for calcium. Nox5 activity is regulated not
only by calcium changes in the cells, but also by calmodulin and by phosphorylation of kinases.
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with the cytoskeleton, lipid rafts/caveolae, and the peri-
nuclear compartment. The Nox2 gene is inducible and is
highly regulated by Ang II and stretch (51, 149). Vascular
Nox2, derived from resident macrophages or vascular cells, is
up-regulated in experimental hypertension, atherosclerosis,
ischemia-reperfusion injury, and neointimal formation
(74, 211). Nox2 is also implicated in stroke in experimental
models (34).
Nox4
Nox4 is found in vascular cells, fibroblasts, adipocytes,
hepatocytes, and renal cells (64, 84, 180). In VSMCs, Nox4 co-
localizes with p22phox and vinculin in focal adhesions and
plays a role in cell migration, proliferation, and cell differen-
tiation (35). Nox4 has been identified in the endoplasmic re-
ticulum, mitochondria, and nucleus, and it is constitutively
active and regulated mainly by its level of expression (8).
Nox4 appears to generate H2O2, although the primary prod-
uct is probably O2
 - , which is rapidly dismutated to H2O2
(202, 232). Nox4 contributes to basal ROS production through
its constitutive activity and to increased ROS generationwhen
induced by Ang II, glucose, tumor necrosis factor a, and
growth factors (90, 127). Recent studies have identified a 28-
kDa Splice Variant of Nox4 located in the nucleus of vascular
cells, which may be important in pathophysiologic effects
through modulation of nuclear signaling and DNA damage
(9). The pathological role of Nox4 is unclear, although it has
been implicated in hypertension, atherosclerosis, and cardio-
vascular and renal complications of diabetes and in re-
modeling of pulmonary arteries in pulmonary hypertension
(181, 206). Nox4-derivd ROS has also been suggested in cel-
lular senescence and aging (104) and in insulin-mediated dif-
ferentiation of adipocytes (177). Recent studies demonstrated
that Nox4 may actually have protective effects, possibly
through Nox4-derived H2O2, which may act as a vasodilator
in some vascular beds (164, 238). This could explain why
mice with targeted endothelial Nox4 overexpression have
lower blood pressure and improved endothelium-dependent
vasodilation versus wild-type controls (164).
Nox5
Nox5 is the most recently identified Nox and is unique: It is
Ca2 + sensitive, possesses a calmodulin-like domain with
Ca2 + binding sites, and does not require any Nox subunits for
its activity (62, 92, 138, 185). Nox5 was first identified in testes
and spleen and, more recently, in vascular cells. 5 splice
variants have been identified: a, b, d, c, and e (157). While the
functional roles for each of these variants have yet to be dis-
covered, all share a number of features common to all Noxs,
including six transmembrane spanning domains, two groups
of heme-spanning histidines, an NADPH-binding motif, and
an FAD-binding domain. Vascular Nox5 is activated by
PDGF, Ang II, and ET-1 and it involves ERK1/2, PI(4, 5)P2,
PKC, and c-Abl (17, 137, 155). Hsp90 binds to and regulates
Nox5 protein stability (56, 126, 33). In human endothelial cells
(ECs), siRNA-mediated Nox5 knockdown reduced Ang II
stimulated ERK1/2 activation, but not that of p38 MAPK or
JNK (56). Nox5 generates ROS in response to increases in
[Ca2 + ]i. Agonists signaling through increased [Ca
2 + ]i (e.g.,
Ang II, ET-1) stimulate Nox5 via its Ca2 + binding hands (13,
33, 138, 156). Binding of calmodulin also enhances Nox5 Ca2 +
affinity, while Ca2 +/calmodulin-dependent kinase II phos-
phorylates Nox5b on Ser475 to increase ROS generation (156).
The ability of Nox5 to respond to Ca2 + -sensitive signaling
may be especially important in vascular cells, where Ca2 + is
critically involved in vascular function (contraction/dilation,
growth). Of the many Ca2 + channels important in regulating
vascular [Ca2 + ]i, transient receptor potential melastatin cation
channel 2 (TRPM2) is interesting in the context of oxidative
stress, as TRPM2 is highly redox sensitive (135, 203).
The significance of this novel isoform in the cardiovascular
system is unknown, and to our knowledge, nothing is known
about vascular Nox5 and hypertension. Since theNox5 gene is
present in humans but absent in rodents, a study of this iso-
form is challenging in the experimental setting.
Antioxidant Defense Mechanisms
In biological systems, the natural defense against ROS
comprises enzymatic and nonenzymatic systems. Nuclear
factor erythroid 2-related factor 2 (Nrf2), a transcriptional
factor, is the master regulator of antioxidant genes and hence
of antioxidant status (44). It may be possible, although still not
proved, that Nrf2 is down-regulated in hypertension, which
could contribute to decreased antioxidant status and conse-
quent oxidative stress. Nrf-2 expression and activity are im-
paired in conditions associated with hypertension, such as
kidney disease and diabetes (101), but the role in hypertension
per se is unknown.
Major enzymatic antioxidants, which are regulated, in
part by Nrf-2, include manganese superoxide dismutase
(MnSOD), catalase, glutathione peroxidases, thioredoxin, and
peroxiredoxin (31, 69, 89). SOD, of which there are three iso-
forms, and catalyze the dismutation of O2
 - into H2O2 and
O2. Of the three SOD isoforms eSOD is themain vascular SOD
(69). Non-enzymatic antioxidants, which act as ROS scaven-
gers, include vitamins A, C, and E; glutathione, billirubin, and
uric acid.
Low antioxidant bioavailability promotes cellular oxida-
tive stress and has been implicated in cardiovascular and re-
nal oxidative damage that is associated with hypertension.
Activity of SOD, catalase, and GSH peroxidase is lower, and
the GSSG/GSH is higher in plasma and circulating cells from
hypertensive patients than normotensive subjects (174).
Moreover, a large population-based cross-sectional study
conducted in more than 20,000 adults participating in the
European Prospective Investigation Into Cancer-Norfolk
demonstrated that individuals with high plasma vitamin C
levels had lower blood pressure than those with low plasma
vitamin C levels (144).
In mice deficient in EC-SOD and in rats in which GSH
synthesis is inhibited, blood pressure is elevated, indicating
that reduced antioxidant capacity is associated with elevated
blood pressure (42). In angiotensinogen-overexpresing mice,
which are hypertensive, catalase overexpression prevented
blood pressure elevation and protected against kidney dam-
age (68). In human studies, plasma vitamin C levels are in-
versely related to blood pressure levels, indicating a potential
blood pressure-lowering effect of this antioxidant (94).
Oxidative Stress and Experimental Hypertension
There is now extensive experimental data showing that
ROS play a role in the development of hypertension, with
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many models of hypertension exhibiting oxidative stress, in-
cluding genetic forms (SHR, SHRSP), surgically induced
(2K1C, aortic banding), hormone-induced (Ang II, ET-1, al-
dosterone, and DOCA), and diet-induced hypertension (salt,
fat) (32, 87, 179). Oxidative stress and inflammation are
common features in cardiac, vascular, renal, and retinal
damage in hypertension, and especially in the context of di-
abetes (32) (Fig. 4). Mice deficient in ROS-generating enzymes
(e.g., Nox2 -/ - , p47phox -/ - , and Nox1 -/ - ) have lower
blood pressure compared with wild-type counterparts, and
Ang II infusion fails to induce hypertension in these mice (15,
109). The exact mechanisms by which ROS influence blood
pressure remain unclear, but many systems are involved, in-
cluding the brain, heart, kidneys, and vessels. In addition,
recent evidence indicates that the immune system may be
involved. Oxidative stress precedes the development of hy-
pertension in experimental models, and it may play a role in
fetal programming and the development of hypertension in
adult life (153). This may be related to alterations in antioxi-
dant status, as impaired renal catalase and glutathione per-
oxide mRNA expression and activity were found to precede
the development of hypertension in SHR (198). Markers of
oxidative stress, such as TBARS, and F2a-isoprostanes, tissue
concentrations of O2
 - and H2O2, and activation of Nox and
xanthine oxidase are increased; whereas levels of NO and
antioxidant enzymes are reduced in experimental hyperten-
sion (61, 222). Moreover cross-talk betweenmitochondria and
Noxs may amplify ROS generation (Fig. 5).
Of the many models of hypertension in which oxidative
stress has been shown to be important, Ang II-dependent
hypertension, is the best characterized. In Ang II-infused rats
and mice, expression of Noxs (Nox1, Nox2, and Nox4), Nox
activity, and ROS generation are increased (27, 226). Ang
II-induced hypertension is also associated with DNA double-
strand breaks and the mutagenic DNA base modification 7,8-
dihydro-8-oxo-guanine, effects that were blocked by the
radical scavenger tempol (21). These data demonstrated oxi-
dative stress-mediated genotoxic effects of Ang II in vivo,
which may contribute to oxidative cardiovascular and kidney
damage in hypertension (129). In p47phox knockout mice and
in gp91phox (Nox2) knockout mice, Ang II infusion failed to
induce hypertension, and these animals do not show the same
FIG. 4. Nox distribution in the heart, kidney, and vessels. Nox homologues are differentially expressed in tissues from the
cardiovascular-renal systems. As illustrated in the figure, Noxs not only play important roles in pathological conditions, but
also regulate a series of responses that are important to the physiology of each cell type or tissue. An increase in ROS
generation and a dysregulation of Nox expression/activity, followed by a decrease in ROS degradation, leads to an increase
in ROS-induced injurious actions and oxidative damage. MMP, matrix metalloprotease; VSMC, vascular smooth muscle cells;
EC, endothelial cells; ECM, extracellular matrix.
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augmentation in O2
 - production, vascular hypertrophy, and
endothelial dysfunction observed in wild-type counterparts
(110). In Ang II-infused mice treated with siRNA targeted to
renal p22phox, renal Nox activity was blunted; ROS forma-
tion was reduced; and blood pressure elevation was pre-
vented (136). On the other hand, overexpression of vascular
p22phox was associated with increased oxidative stress and
vascular dysfunction, but no significant increase in blood
pressure (114). Treatment with non-specific pharmacological
inhibitors of Nox, such as apocynin or diphenylene iodinium,
or gp91dstat, a novel-specific inhibitor of Nox, reduced vas-
cular O2
 - production, prevented cardiovascular remodeling,
and attenuated development of hypertension in Ang II-
dependent hypertension (73, 166). Nox1-deficient mice have
reduced vascular O2
 - production, and blood pressure ele-
vation in response to Ang II is blunted (63); whereas in
transgenic mice in which Nox1 is overxpressed in vascular
smoothe muscle cells in the vascular wall, Ang II-mediated
vascular hypertrophy and blood pressure elevation are en-
hanced (49). However, in a model of chronic Ang II-dependent
hypertension, where transgenic mice expressing human
renin (which exhibit an Ang II-sensitive hypertensive phe-
notype) were crossed with Nox2-/ - or Nox1 -/ -mice, de-
velopment of hypertension was not prevented even though
oxidative stress was reduced, suggesting that Noxs may be
more important in acute than in chronic hypertension (234). It
should be stressed that in these Nox knockout or transgenic
studies, baseline cardiovascular phenotypes of mice are sur-
prisingly normal and it is only in the context of a challenge,
such as with Ang II or salt, that mice exhibit vascular and
blood pressure aberrations.
Oxidative stress in the brain plays an important role in the
development of hypertension (103, 231, 239). Nox-induced
ROS production in the rostral ventrolateral medulla causes
sympathoexcitation in hypertensive rats, through mecha-
nisms that involve NO and pro-inflammatory processes.
Transgenic (mRen2)27 rats have increased medullary tissue
Nox activity and increased ROS production in isolated mito-
chondria (146). Free radical signaling in the subfornical organ
(SFO), an important forebrain circumventricular organ, is
critical for sympathetic activation, driving the elevation in
blood pressure in Ang II-infused mice (29). Suppression of
ROS generation in the SFO by overexpression of CuZn-SOD
prevented development of hypertension in these mice. The
SFO mediates ROS-related effects through activation of the
paraventricular hypothalamic nucleus, causing increased
plasma vasopressin, up-regulation of endothelin-1 in cerebral
resistance arterioles, and activation of endothelin type A
FIG. 5. Interactions between Nox and mitochondria. Noxs can regulate mitochondrial function and vice versa. Through
production of ROS, Noxs are able to induce mitochondrial dysfunction, leading to an increase in the production of ROS by
the mitochondria. Either by ROS generation or by release of second messengers, the mitochondria will increase the expression
and activation of Noxs, further increasing oxidative stress, activation of redox signaling, and ROS-induced effects. It has also
been reported that Noxs and mitochondria colocalize and may regulate their respective activities.
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receptors and through activation of cerebrovascular AT1 re-
ceptors by Ang II (29). Both pathways mediate vasomotor
dysfunction by inducing vascular oxidative stress. The find-
ings implicate the SFO and its efferent hypothalamic path-
ways in the cerebrovascular alterations induced by Ang II,
and they identify vasopressin and endothelin-1 as potential
therapeutic targets to counteract the damaging effects of hy-
pertension on the brain.
Although it is becoming increasingly clear that ROS pro-
duced in the central nervous system promote sympathetic
outflow, inflammation, and hypertension, the contribution of
Noxs to these processes is unclear (38). In mice in which
p22phoxwas deleted in the SFO, Ang II infusion failed to elicit
a hypertensive response (120). These findings confirmed the
importance of Noxs in the SFO as a critical determinant of the
blood pressure and vascular inflammatory responses to Ang
II (120). In addition toNox-derived ROS, ER stress in the brain
SFO is important in Ang II-induced hypertension (235).
Additional sources of Nox-generated ROS in Ang II-
induced hypertension are cells of the immune system, spe-
cifically T cells. In mice which lack lymphocytes (RAG1 -/ -
mice), hypertensive responses to Ang II are reduced, a re-
sponse that is restored by adoptive transfer of T-lymphocytes,
but not of B-lymphocytes (223). T cells influence blood pres-
sure elevation by interacting with B7 ligands (CD80 and
CD86) and the T-cell coreceptor CD28 (223) and through the
dysegulation of T-regulatory and T-effector cells (14). Adop-
tive transfer of T-regulatory lymphocytes cells suppresses
Ang II-mediated vascular injury and hypertension, in part, by
reducing Nox-derived ROS generation (14).
Other atypical sources of ROS that may impact vascular
redox status include perivascular adipose tissue (23, 80, 148).
Adipose tissues possesses functionally active Nox4, which
generates ROS, an important modulator of adipocyte biology
and adipocytokine production. Perivascular adipose tissue
influences vascular tone through adipocyte-derived vasoac-
tive factors and ROS, effects that may be enhanced in hyper-
tension, especially in the context of obesity, metabolic
syndrome, and diabetes (148).
In order to further support a role for oxidative stress in
experimental hypertension, treatment of hypertensive rats
or mice with antioxidant vitamins, SOD mimetics (tempol
[4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl]), free radical
scavengers, or tetrahydrobiopterin (BH4) attenuate or prevent
development of hypertension and its associated target organ
damage (37, 72).
ROS and Noxs in Human Vessels
Although vascular Noxs have been well characterized in
experimental models of hypertension, with most studies
demonstrating increased expression and activity of Nox1,
Nox2, and Nox4 in a site- and cell-specific manner, little is
known about vascular Noxs in human hypertension. Char-
acterization of Noxs in human vessels has focused mainly on
discarded surgical tissue from patients undergoing bypass
surgery. Results from extensive human studies by the Chan-
non group showed increased vascular Nox activity and ex-
pression of Nox2, Nox4, and p22phox, but not of Nox1, in
patients with coronary artery disease or diabetes (10, 76–78).
Others showed that vascular Nox5 expression is increased in
patients with atherosclerosis and cardiac disease (18, 178,
195). Hahn et al. demonstrated the presence of Nox5 expres-
sion in human intramyocardial blood vessels and cardio-
myocytes, with significant increases after myocardial
infarction (79). In a recent comprehensive descriptive study,
Pandey et al. (157) reported that Nox5 is present in human
saphenous vein and internal mammary artery, cultured hu-
manVSMCs, and endothelium, but not in fibroblasts, with the
a and b isoforms being most abundant in vascular cells.
Adenovirus-mediated overexpression of Nox5 promoted
phosphorylation of MAPK in ECs and VSMCs (195), which is
similar to our studies in Ang II-stimulated Nox5-containing
cells (151, 228). These studies, although informative of human
Nox expression, have limitations, as they are essentially de-
scriptive and do not reveal much insight into the mechanisms
of oxidative stress. However, such studies consistently
demonstrate up-regulation of vascular Noxs in cardiovas-
cular disease, indicating their potential importance in such
conditions.
ROS, Noxs, and Vascular Function: Clues from Studies
in Patients with Hereditary Deficiency of Nox
Practical and ethical issues limit the direct study of Noxs
and ROS in human cardiovascular disease. However, a series
of studies by Viola and colleagues, inwhich patients withNox
deficiency (chronic granulomatous disease) were studied,
demonstrated that Noxs and ROS are important in the regu-
lation of vascular tone (122, 124, 225). This was evidenced by
the following: patients with Nox 2 or p47phox deficiency had
significantly higher forearm-mediated dilation and lower se-
rum levels of soluble Nox2-derived peptide (marker of Nox2
activation) and 8-iso-PGF2a levels compared with healthy
subjects; platelets from patients with Nox2 deficiency have
reduced isoprostane formation; patients with CGD are pro-
tected from ischemia-reperfusion injury (121, 122, 124, 225).
Moreover, women carriers of hereditary deficiency of Nox2
had higher flow-mediated dilation, lower intima-media
thickness, reduced urinary isoprostanes and serum Nox2 ac-
tivity, increasedNO bioavailability, and higher serum nitrite/
nitrate compared with controls, suggesting reduced vascular
damage and atherosclerotic burden in carriers of Nox2 defi-
ciency (224). Taken together, these studies implicate a role
for Nox and ROS in the regulation of endotehlial function
and vascular tone. However, it should be kept in mind that
these findings may be influenced by the clinical conditions
of these patients, as they have life-threatening infections, that
are often treated prophylactically with antibiotics and anti-
fungal agents.
ROS, Oxidative Stress and Human Hypertension
Hypertensive patients exhibit higher levels of plasma
H2O2, increased plasma, and urinemarkers of oxidative stress
such as TBARS, oxidized low-density lipoprotein (oxLDL),
and 8 iso-prostane and reduced antioxidant capacity, com-
pared with normotensive subjects (20, 171, 184, 205, 229).
Isoprostanes are stereoisomers of prostaglandins, which are
formedmainly by non-enzymatic peroxidation of arachidonic
acid by ROS. Plasma levels of oxLDL are influenced primarily
by the magnitude of oxidative stress within the vascular wall
as well as by the susceptbility of LDL to oxidation. Treatment
with antihypertensive drugs reduces oxidative stress bio-
markers, in some cases independently of blood pressure
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lowering. In 2011, the European Food Safety Authority ac-
cepted urine isoprostanes as a biochemical marker of oxida-
tive stress (55). However, testing of such biomarkers is not
routine practice in the clinic, and standardizedmethodologies
are not yet available at hospital laboratories.
Due to the potential predictive value of biomarkers, there is
growing interest in identifying more specific and direct indi-
ces of oxidative stress. Recent advances in the field have
focused on redox proteomics in which oxidative post-
translational modifications can be identified in protein targets
of oxidative or nitrosative stress (193). Redox proteomics
technologies can identify oxidized proteins in serum, plasma,
and urine. Advanced oxidation proteins are variants pri-
marily of albumin and fibrinogen and have been identified in
plasma and serum from patients with chronic kidney disease
and hypertension (173, 183). Post-translational modifications
of protein residues by ROS include thiol oxidation and car-
bonylation. In a large cohort of Chinese adults, plasma reac-
tive carbonyl species was positively associated with blood
pressure levels and was found to be an important risk factor
for developing hypertension (36). Nitration of proteins, es-
pecially modification of tyrosine to 3-nitrotyrosine, is another
form of redox modification and is increased in serum proteins
in patients with hypertension, chronic kidney disease, and
diabetes (25, 131, 217).
Normotensive subjects with a family history of hyperten-
sion have greater ROS production than blood pressure-
matched subjects without a family history of hypertension,
suggesting a genetic component that is associated with ele-
vated production of free radicals (57, 105, 108). Racial differ-
ences in oxidative stress and inflammation have also been
demonstrated. Human umbilical vein endothelial cells
(HUVEC) from African Americans exhibited higher levels of
NO, IL-6, p47phox, Nox2, and Nox4 and lower SOD activity
than HUVECs from Caucasians (169).
ROS production is increased in VSMCs from resistance
arteries of hypertensive patients, and this is associated with
up-regulation of vascular Nox (75, 112, 142, 207, 213, 233).
The importance of Nox in human cardiovascular disease is
supported by studies showing that polymorphisms in Nox
subunits are associated with increased atherosclerosis and
hypertension. In particular, the - 930(A/G) polymorphism
in the p22(phox) promoter may be a novel genetic marker
that is associated with hypertension. An association be-
tween the p22phox - 930 G polymorphism has been asso-
ciated with blood pressure in normotensive subjects (100).
The C242T CYBA polymorphism is associated with essential
hypertension, and hypertensive patients carrying the CC
genotype of this polymorphism exhibit features of Nox-
mediated oxidative stress and endothelial damage and are
prone to cerebrovascular disease. The T allele of the p22-
phox C242T polymorphism is also associated with higher
left ventricular mass/height and increased Nox activity in
Brazilian hypertensive patients, suggesting that genetic
variation within Nox components may modulate left ven-
tricular remodeling in subjects with hypertension (176). In a
Japanese population, the G( - 930)A polymorphism of CYBA
was confirmed to be important in the pathogenesis of
hypertension (141). Polymorphisms of the xanthine oxi-
dase gene (- 337GA and 565+ 64CT) have also been shown
to be related to blood pressure and oxidative stress in
hypertension (237).
In addition to essential hypertension, oxidative stress is
found in other forms of hypertension. Patients with primary
hyperaldosteronism exhibit increased levels of plasma ROS
and markers of subclinical inflammation compared with es-
sential hypertensive patients (60, 196). These findings were
associated with increased cardiac fibrosis, phenomena that
were independent of blood pressure elevation but related to
proinflammatory and oxidative stress effects of aldosterone.
Hypertension during pregnancy was also found to be asso-
ciated with oxidative stress as evidenced by increased TBARS
levels during labor (5). This was related to reduced plasma
SOD activity and increased plasmaGSH-Pxwith no change in
GSH-Red activity (5). Alterations in antioxidant and pro-
oxidant status during pregnancy may constitute an increased
risk factor for hypertensive pregnant women. Elderly patients
(*75 years) who exhibit endothelial dysfunction and de-
creased antioxidant capacity responded positively to oral
antioxidant therapy, with improved flow-mediated vasodi-
lation, decreased plasma TBARS levels, and increased anti-
oxidants (230). However, in young individuals (*25 years),
antioxidant therapy worsened endothelial function, suggest-
ing that the age-related impairment is attributed, at least in
part, to oxidative stress.
Decreased antioxidant defense mechanisms also contribute
to oxidative stress in human hypertension. Patients with es-
sential hypertension exhibit reduced activity and decreased
plasma levels of antioxidant enzymes, including SOD, gluta-
thione peroxidase, and catalase (192). Decreased levels of
antioxidant vitamins A, C, and E have been shown in newly
diagnosed, untreated hypertensive patients compared with
normotensive controls (143). Nrf-2, the master transcription
factor that regulates antioxidant genes, is protective in ma-
ternal diabetes-induced perinatal hypertension (30, 221).
Antioxidant vitamins reduced blood pressure and arterial
stiffness in patients with diabetes (240), but had no effect in
postmenopausal women or in healthy subjects (140). Popu-
lation studies have demonstrated an inverse association be-
tween plasma vitamin C levels and vitamin C consumption
with blood pressure (28, 139), and a recent meta-analysis re-
ported that vitamin C supplementation reduced systolic and
diastolic blood pressure (147). In patients with white coat
hypertension, serum protein carbonyl (indicating protein
oxidation) was increased and endogenous antioxidant pro-
teins (protein thiol, SOD, glutathione) were decreased com-
pared with normotensive individuals, further supporting a
relationship between low antioxidant capacity, increased ox-
idative stress, and hypertension (201).
ROS as Therapeutic Targets in Human Hypertension
Considering the possible pathophysiological role of oxi-
dative stress in hypertension and other cardiovascular dis-
orders, and the convincing experimental data, it is reasonable
to imagine that reducing ROS bioavailability through anti-
oxidants, ROS scavengers, and Nox inhibitors would have
protective and blood pressure-lowering effects. Antioxidants
that have been commonly studied, including vitamins A, C,
and E, co-enzyme Q, beta carotene, polyphenols, and flavo-
noids. A recent meta-analysis evaluating the effects of vitamin
C supplementation on blood pressure reported that vitamin C
supplementation reduces blood pressure by 3.84/1.48mmHg
(147). However, findings are inconsistent, and clinical trial
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data are inconclusive, with most large antioxidant clinical
trials failing to demonstrate beneficial cardiovascular effects
(129, 133, 187). Findings from the PhysiciansHealth Study II, a
randomized double-blind, placebo-controlled trial of a com-
mon dailymultivitamin inwhich 14,641menwere studied for
11.2 years, revealed no significant effect of multivitamin
supplementation on cardiovascular events (188). Similar
negative results have been reported for many other large
antioxidant trials, which have been recently reviewed (83, 85,
97, 129, 133, 187). In addition, clinical trials examining the
effects of antioxidant vitamins (vitamins C and E) in the
prevention of pre-eclampsia and gestational hypertension
have been negative (132, 168). Reasons for these disappoint-
ing results are numerous, but as Brieger et al. (22) hypothesize,
‘‘antioxidant supplementation is too late, too little and too
non-specific.’’
Based on the lack of evidence proving antioxidant benefits
in cardiovascular diseases, antioxidant supplementation is
not recommended for the prevention or treatment of hyper-
tension. However, most hypertension guidelines recommend
that the general population consumes a diet rich in fruits,
vegetables, and whole grains, which is a diet rich in anti-
oxidants (123). The low sodium Dietary Approaches to Stop
Hypertension (DASH) diet reduces oxidative stress and im-
proves vascular function in salt-sensitive patients (6, 88).
Another important lifestyle modification that may have
cardiovascular protective and blood pressure-lowering effects
by reducing oxidative stress is exercise. In experimental
models of hypertension and in patients with coronary artery
disease, exercise reduced vascular Nox activity and ROS
production, ameliorated vascular injury, and reduced blood
pressure (1). Resistance training in men decreased circulating
levels of matrix metalloprotease-9 and 8-isoprostane (43).
However, in elderly patients, combining antioxidant therapy
with exercise negated blood pressure-lowering beneficial
effects of exercise (43).
Clinical studies examining the effects of xanthine oxidase
inhibitors (70, 204), tetrahydrobiopterin (sapropterin dihy-
drochloride [6r-bh4]) (167), and N-acetylcysteine (165) have
demonstrated improved vascular function and blood pres-
sure lowering in patients with hypertension, chronic kidney
disease, and pulmonary hypertension. However, a recent
clinical trial demonstrated that in patients with CAD, oral
tetrahydrobiopterin treatment failed to improve endothelial
function or cardiovascular outcomes, possibly due to auto-
oxidation of the compound (47).
Some of the beneficial effects of classical antihypertensive
agents such as ß-adrenergic blockers, ACE inhibitors, AT1
receptor antagonists, and Ca2 + channel blockers may be
mediated, in part, by decreasing vascular oxidative stress (59,
125, 154). These effects have been attributed to the direct in-
hibition of Nox activity and to intrinsic antioxidant properties
of the drugs. However, some studies failed to show changes in
oxidative stress despite significant blood pressure lowering
by classical antihypertensive drugs (106, 191).
Other commonly used drugs have also been shown to re-
duce oxidative stress in patients with cardiovascular risk
factors. Fenofibrate, a lipid-lowering agent with pleiotropic
actions, improved endothelial function, measured by brachial
flow-mediated dilation, in middle-aged and older normoli-
pidemic adults by reducing oxidative stress and by increasing
endothelial NOS expression and activity (227).
Noxs as Putative Targets in the Treatment
of Hypertension
Antioxidants and radical scavengers increase rates of ROS
degradation, whereas inhibitors of ROS-generating enzymes
decrease rates of ROS formation. Of the many enzymes that
are potential therapeutic targets are Noxs. Due to this, there
has been enormous interest in the development of agents that
inhibit Noxs in an isoform-specific manner (91, 102, 194, 197).
Different strategies have been employed, including small-
molecule inhibitors, peptide Nox inhibitors, and siRNAS.
Several pharmacological compounds have been registered as
Nox inhibitors in the patent literature (102). First-generation
Nox inhibitors, including apocynin and diphenylene iodi-
nium, are non specific, lack selectivity, and havemultiple ‘‘off-
target’’ side effects. Newer-generation NOX inhibitors are
more specific and selective. To date, two different classes of
compounds have been claimed as potent selective and orally
active bioavailable Nox inhibitors: pyrazolopyridines
(GKT136901 and GKT137831) and triazolopyrimidine deriv-
atives (VAS2870 and VAS3947) (39, 91, 102, 194, 197). These
agents target mainly Nox1 and Nox4, and, apparently, have a
few ‘‘off-target’’ side effects (22, 217). The exact mechanisms
by which GKT compounds inhibit Nox activity remain un-
clear, but they may act as competitive substrate inhibitors, as
they structurally resemble NADPH. GKT137831 has already
undergone safety studies in humans and was found to be safe
and well tolerated (86). Its use will soon be tested in patients
with diabetic nephropathy, and future studies may evaluate
the effects on hypertension and other cardiovascular diseases
(86). Although much research is still needed in the field, the
clinical utility of Nox-specific inhibitors is promising.
Conclusions
Compelling findings from experimental and animal studies
indicate a role for oxidative stress and Noxs in the etiology of
hypertension. However, there is no direct clinical proof that
oxidative stress causes hypertension in humans. What is clear
from experimental and translational research is that dysregu-
lation of Noxs increased ROS generation-altered redox
signaling, and oxidative injury may be important in the path-
ophysiology of increased blood pressure, in large part through
effects on endothelial function, vascular tone, arterial re-
modeling, and vascular inflammation. The recently identified
Nox, Nox5, may be particularly important in vascular injury
and cardiovascular disease in humans. More translational and
clinical research in the field of oxidative stress andhypertension
is needed, especially in the development of sensitive, specific,
and reliable biomarkers and assays to assess the redox status of
humans in health and disease. Clinical trials are designed to
address the role of ROS specifically in the development of hy-
pertension.With a better understanding of ROS (patho)biology
in humans, it should be possible to target therapies more ef-
fectively so that damaging effects of ROS can be prevented or
ameliorated. Such approachesmay have potential benefit in the
treatment of redox-sensitive pathologies that are associated
with cardiovascular disease, including hypertension.
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Abbreviations Used
Ang II¼ angiotensin II
BH4¼ tetrahydrobiopterin
CKD¼ chronic kidney disease
ECM¼ extracellular matrix
ECs¼ endothelial cells
eNOS¼ endothelial nitric oxide synthase
H2O2¼hydrogen peroxide
HUVEC¼human umbilical vein endothelial cells
MAPK¼mitogen-activated protein kinases
MMP¼matrix metalloprotease-9
MnSOD¼manganese superoxide dismutase
NADPH¼nicotinamide adenine dinucleotide
phosphate
NO¼nitric oxide
NOS¼nitric oxide synthase
Noxs¼NADPH oxidase
Nrf2¼nuclear factor erythroid 2-related factor 2
oxLDL¼ oxidized low-density lipoprotein
PDGF¼platelet-derived growth factor
ROS¼ reactive oxygen species
SFO¼ subfornical organ
TBARS¼ thiobarbituric acid-reactive substances
TRPM2¼ transient receptor potential melastatin
cation channel 2
TSP1¼ thrombospondin-1
VSMC¼vascular smooth muscle cells
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